Type 2 inflammation in asthma and other airway diseases.
Maspero J, Adir Y, Al-Ahmad M, Celis-Preciado CA, Colodenco FD, Giavina-Bianchi P, Lababidi H, Ledanois O, Mahoub B, Perng DW, Vazquez JC, Yorgancioglu A.
Maspero J, et al.
ERJ Open Res. 2022 Aug 1;8(3):00576-2021. doi: 10.1183/23120541.00576-2021. eCollection 2022 Jul.
ERJ Open Res. 2022.
PMID: 35923421
Free PMC article.
Review.
Asthma is a heterogenous disease; therefore, identification of biomarkers and early targeted treatment is critical for patients inadequately managed by inhaled corticosteroids and long-acting beta-agonists alone. The Global Initiative for Asthma guidelines recommend add-on …
Asthma is a heterogenous disease; therefore, identification of biomarkers and early targeted treatment is critical for patients inadequately …